Zimycan “Not Approvable” Letter Could Mean One-Year Approval Delay
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Barrier Therapeutics believes it may have to conduct a second absorption study for its antifungal ointment Zimycan following receipt of a "not approvable" letter May 24